

antibody, Fab, F(ab)'₂ or single chain antibody is administered to said human at a dosage range of between about 0.01 and 200 mg/kg body weight of said human.

146. (added) A method for treating vasculitis in a human, other than a transplant recipient, comprising the step of administering to said human an antibody, Fab, F(ab)'₂ or a single chain antibody, which binds specifically to an antigen specifically bound by monoclonal antibody 5c8, produced by the hybridoma having ATCC Accession No. HB 10916, wherein said antibody, Fab, F(ab)'₂ or single chain antibody is administered to said human at a dosage range of between about 0.01 and 50 mg/kg body weight of said human.

147. (added) A method for treating vasculitis in a human, other than a transplant recipient, comprising the step of administering to said human an antibody, Fab, F(ab)'₂ or a single chain antibody, which binds specifically to an antigen specifically bound by monoclonal antibody 5c8, produced by the hybridoma having ATCC Accession No. HB 10916, wherein said antibody, Fab, F(ab)'₂ or single chain antibody is administered to said human at a dosage range of between about 1 and 30 mg/kg body weight of said human.

C2
Cont.
148. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'₂ or single chain antibody specifically inhibits cell activation by CD40 ligand of CD40-bearing cells which are involved in an inflammatory response.

149. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'₂ or single chain antibody inhibits binding of CD40 ligand to CD40 on the surface

of endothelial cells, fibroblasts, epithelial cells, T cells, basophils, macrophages or dendritic cells in said human.

150. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'₂ or single chain antibody inhibits the interaction between CD40 ligand and CD40 on the surface of endothelial cells, fibroblasts, epithelial cells, T cells, basophils, macrophages or dendritic cells in said human.

151. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'₂ or single chain antibody is effective to inhibit transmigration of inflammatory cells across a barrier of endothelial cells in said human.

152. (added) The method according to any one of claims 145 to 147, wherein said antibody is a monoclonal antibody or a polyclonal antibody.

C2
cont.
153. (added) The method according to any one of claims 145 to 147, wherein said antibody is selected from the group consisting of: chimeric antibodies, primatized antibodies, humanized antibodies and antibodies which include a CDR region from a first human and an antibody scaffold from a second human.

154. (added) The method according to any one of claims 145 to 147, wherein said antibody is monoclonal antibody 5c8 which is produced by the hybridoma having ATCC Accession No. HB 10916.

155. (added) The method according to any one of claims 145 to 147, wherein said antibody is a humanized monoclonal antibody 5c8 or a primatized monoclonal antibody 5c8.

156. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'₂ or single chain antibody is selected by a screening method, which comprises the steps of:

- (a) isolating a sample of CD40-bearing cells which are involved in an inflammatory response;
- (b) culturing said sample under conditions permitting activation of the CD40-bearing cells;
- (c) contacting said sample with:
 - (i) cells expressing a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916, or
 - (ii) a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916,under conditions which permit activation of said CD40-bearing cells;
- (d) contacting said sample with an antibody, Fab, F(ab)'₂ or a single chain antibody, under conditions which permit said antibody, Fab, F(ab)'₂ or single chain antibody to inhibit activation of said CD40-bearing cells; and
- (e) determining whether the (i) cells expressing a protein which is specifically recognized by

C²
cont.

monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916, or (ii) protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916, activate the CD40-bearing cells in the presence of the antibody, Fab, F(ab)'2 or single chain antibody.

157. (added) The method according to claim 156, wherein said sample of CD40-bearing cells is isolated from a tissue.

158. (added) The method according to claim 156, wherein said sample of CD40-bearing cells is selected from the group consisting of: cell lines in culture, cells isolated from an animal and cells isolated from a body fluid.

159. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'2 or single chain antibody is administered to said human by a parenteral route.

C2
Cont.
160. (added) The method according to claim 159, wherein said parenteral route is selected from the group consisting of: intravenous, intravascular, intraarterial, subcutaneous, intramuscular, intratumor, intraperitoneal, intraventricular, intraepidural, oral, nasal, ophthalmic, rectal, topical and inhalation routes.

161. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'2 or single chain antibody is administered to said human by sustained release administration.

162. (added) The method according to claim 161, wherein said sustained release administration comprises depot injection of an erodible implant.

163. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'2 or single chain antibody is administered to said human at intervals ranging from each day to every other month.

164. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'2 or single chain antibody is administered to said human daily for the first three days of treatment, after which the antibody, Fab, F(ab)'2 or single chain antibody is administered every 3 weeks, with each administration being intravenously at 5 or 10 mg/kg body weight of said human.

C2
Cont
165. (added) The method according to any one of claims 145 to 147, wherein said antibody, Fab, F(ab)'2 or single chain antibody is administered to said human daily intravenously at a dosage of 5 mg/kg body weight of said human for the first three days of treatment, after which the antibody, Fab, F(ab)'2 or single chain antibody is administered subcutaneously or intramuscularly every week at a dosage of 10 mg/kg body weight of said human.

166. (added) The method according to any one of claims 145 to 147, wherein a single dose of said antibody, Fab, F(ab)'2 or single chain antibody is administered to said human parenterally at 20 mg/kg body weight of said human, followed by administration of the antibody, Fab, F(ab)'2 or single chain antibody subcutaneously or intramuscularly every week at a dosage of 10 mg/kg body weight of said human.
